---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-028250"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-08-18T11:01:23+00:00"
generated_at: "2026-08-18T11:05:18.896085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex partners with US CDMO for diabetes gene therapy manufacturing scale-up

## Summary
- On Aug 18, 2026, Genprex entered a development/manufacturing agreement with a leading US-based CDMO.
- Agreement transitions AAV-based diabetes candidate from research-grade to clinical/commercial cGMP production.
- CDMO will supply drug product for IND-enabling preclinical studies and future clinical trials.
- Program targets T1D and T2D by delivering Pdx1 and MafA genes via AAV; also exploring non-viral LNP approach.
- Manufacturing roadmap includes process optimization, scale-up, analytical qualification, and GMP compliance.

## SEC filing metadata
- accession: 0001437749-26-028250
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-08-18T11:01:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926028250/0001437749-26-028250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926028250/gnpx20260817_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-028250
- JSON: https://secwatch.observer/filing/0001437749-26-028250.json
- Plain text: https://secwatch.observer/filing/0001437749-26-028250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.